| Autor: |
Lorizzo, Katia, Fazio, Nicola, Radice, Davide, Boselli, Sabrina, Ariu, Leonardo, Zampino, Maria Giulia, Nolè, Franco, Magni, Elena, Ardito, Raffaele, Minchella, Ida, Rocca, Andrea, Di Meglio, Giovanni, Squadroni, Michela, de Braud, Filippo |
| Předmět: |
|
| Zdroj: |
Cancer Chemotherapy & Pharmacology; Jul2009, Vol. 64 Issue 2, p301-306, 6p, 3 Charts |
| Abstrakt: |
Second-line chemotherapy in patients with metastatic gastric cancer (MGC) pre-treated with cisplatin is not a standard option. We studied a combination of irinotecan, fluorouracil and folates. Patients progressive to cisplatin-based chemotherapy were enrolled. Irinotecan 180 mg/m2, folinic acid 200 mg/m2, and fluorouracil 400 mg/m2 were given on day 1, immediately followed by fluorouracil 2,400 mg/m2 46 h continuous infusion (simplified FOLFIRI), every 2 weeks. Between June 2002 and May 2003, 28 patients were treated. Median age was 57 years (range 38–68). Most patients had a distal primary (90%), and metastatic disease (71%). Partial response was obtained in six patients (21%, 95% CI 8–41) and stable disease in eight (21%, 95% CI 13–41). Among the six responsive patients three were refractory to docetaxel. At a median follow-up of 2.9 years median time to progression was 4 months (95% CI: 2–5), and median overall survival was 5 months (95% CI 4–9). Toxicity was mild, without treatment-related deaths or life-treating adverse events. Simplified FOLFIRI was moderately active and well tolerated in unselected patients with MGC pre-treated with cisplatin-based chemotherapy. Its role in patients refractory to taxanes is promising and warrants further investigation. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink